NIKKEI 225
28,249.24 +73.37 (+0.26%) HANG SENG
20,045.77 -156.17 (-0.77%) CRUDE OIL
90.26 +1.25 (+1.40%) GOLD FUTURES
1,804.20 +13.00 (+0.73%) DOW
32,838.41 +34.94 (+0.11%) BTC-GBP
19,666.57 +353.57 (+1.83%)
Genmab A/S (GMAB)
| Previous close | 35.15 |
| Open | 35.12 |
| Bid | 34.89 x 900 |
| Ask | 34.91 x 1100 |
| Day's range | 34.36 - 35.40 |
| 52-week range | 26.19 - 49.07 |
| Volume | |
| Avg. volume | 670,980 |
| Market cap | 22.959B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 52.81 |
| EPS (TTM) | 0.66 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.70 |
- Globe Newswire
Genmab Improves Its 2022 Financial Guidance
Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on May 11, 2022. The improved guidance is driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the positive net foreign exchange impact of the strong U.S. Dollar. Genmab expects its 2022 revenue to be in the range of DKK 12,000 – 13,000 million, an increase to th
- Globe Newswire
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than August 31, 2022 and comprises up to 370,000 shares. The following transactions were executed under the program from August 1, 2022 to August 5, 2022: No.
- Globe Newswire
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
COPENHAGEN, Denmark; August 5, 2022 Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumorsExpanded collaboration leverages Genmab’s proprietary HexaBody® technology platform to develop novel monospecific antibodies First monospecific antibody candidate GEN1053/BNT313 planned to enter clinical trials by the end of 2022 Genmab and BioNTech will continue to share costs and potential future profits on a 50:50 basis Genmab A/S (Nasdaq: GMAB)
